GeneBioTech Co. ,Ltd (KOSDAQ:086060)
South Korea · Delayed Price · Currency is KRW 4,300.00
+15.00 (0.35%)
Last updated: Aug 7, 2025
Verve Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 85,654 | 82,959 | 79,477 | 82,759 | 62,814 | 59,119 | Upgrade |
Other Revenue | - | - | - | -0 | -0 | - | Upgrade |
| 85,654 | 82,959 | 79,477 | 82,759 | 62,814 | 59,119 | Upgrade | |
Revenue Growth (YoY) | 6.71% | 4.38% | -3.96% | 31.75% | 6.25% | 1.50% | Upgrade |
Cost of Revenue | 72,316 | 69,589 | 65,825 | 72,409 | 55,374 | 49,685 | Upgrade |
Gross Profit | 13,337 | 13,370 | 13,652 | 10,349 | 7,439 | 9,435 | Upgrade |
Selling, General & Admin | 8,460 | 8,285 | 8,411 | 7,446 | 6,472 | 6,252 | Upgrade |
Research & Development | 880.46 | 875.1 | 837.22 | 765.04 | 820.81 | 1,033 | Upgrade |
Other Operating Expenses | 96.65 | 102.78 | 104.84 | 108.26 | 106.95 | 99.16 | Upgrade |
Operating Expenses | 9,630 | 9,526 | 9,679 | 8,792 | 7,893 | 10,531 | Upgrade |
Operating Income | 3,707 | 3,844 | 3,973 | 1,557 | -453.15 | -1,097 | Upgrade |
Interest Expense | -652.77 | -642.98 | -581.38 | -276.45 | -152 | - | Upgrade |
Interest & Investment Income | 835.81 | 800.59 | 669.56 | 263.92 | 127.25 | - | Upgrade |
Currency Exchange Gain (Loss) | -485.16 | -639.97 | -138.66 | 23.26 | -223.24 | 700.7 | Upgrade |
Other Non Operating Income (Expenses) | 38.9 | 19.06 | 20.65 | 247.09 | -129.9 | -37.56 | Upgrade |
EBT Excluding Unusual Items | 3,444 | 3,380 | 3,943 | 1,815 | -831.03 | -433.68 | Upgrade |
Gain (Loss) on Sale of Assets | 104.26 | 122.26 | 20.69 | -0 | -5.88 | 13.85 | Upgrade |
Asset Writedown | - | - | -589.54 | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | -0.85 | - | Upgrade |
Pretax Income | 3,548 | 3,503 | 3,374 | 1,815 | -837.76 | -419.83 | Upgrade |
Income Tax Expense | 617.48 | 637.3 | 782.7 | 291.39 | -353.36 | -358.37 | Upgrade |
Earnings From Continuing Operations | 2,930 | 2,865 | 2,591 | 1,523 | -484.4 | -61.47 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | -3,370 | Upgrade |
Net Income to Company | 2,930 | 2,865 | 2,591 | 1,523 | -484.4 | -3,432 | Upgrade |
Minority Interest in Earnings | - | - | - | - | - | 1,090 | Upgrade |
Net Income | 2,930 | 2,865 | 2,591 | 1,523 | -484.4 | -2,341 | Upgrade |
Net Income to Common | 2,930 | 2,865 | 2,591 | 1,523 | -484.4 | -2,341 | Upgrade |
Net Income Growth | 12.51% | 10.57% | 70.12% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | 9 | Upgrade |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | 9 | Upgrade |
Shares Change (YoY) | 0.13% | - | - | - | - | - | Upgrade |
EPS (Basic) | 340.34 | 332.76 | 300.95 | 176.91 | -56.26 | -271.91 | Upgrade |
EPS (Diluted) | 340.34 | 332.76 | 300.95 | 176.91 | -56.26 | -271.91 | Upgrade |
EPS Growth | 12.36% | 10.57% | 70.12% | - | - | - | Upgrade |
Free Cash Flow | -1,608 | -1,564 | 6,838 | -4,834 | -5,816 | -1,895 | Upgrade |
Free Cash Flow Per Share | -186.79 | -181.68 | 794.19 | -561.41 | -675.39 | -220.06 | Upgrade |
Dividend Per Share | - | - | - | - | - | 30.000 | Upgrade |
Gross Margin | 15.57% | 16.12% | 17.18% | 12.50% | 11.84% | 15.96% | Upgrade |
Operating Margin | 4.33% | 4.63% | 5.00% | 1.88% | -0.72% | -1.85% | Upgrade |
Profit Margin | 3.42% | 3.45% | 3.26% | 1.84% | -0.77% | -3.96% | Upgrade |
Free Cash Flow Margin | -1.88% | -1.89% | 8.60% | -5.84% | -9.26% | -3.21% | Upgrade |
EBITDA | 5,073 | 5,212 | 5,311 | 2,843 | 791.25 | 950.17 | Upgrade |
EBITDA Margin | 5.92% | 6.28% | 6.68% | 3.44% | 1.26% | 1.61% | Upgrade |
D&A For EBITDA | 1,366 | 1,368 | 1,338 | 1,286 | 1,244 | 2,047 | Upgrade |
EBIT | 3,707 | 3,844 | 3,973 | 1,557 | -453.15 | -1,097 | Upgrade |
EBIT Margin | 4.33% | 4.63% | 5.00% | 1.88% | -0.72% | -1.85% | Upgrade |
Effective Tax Rate | 17.40% | 18.20% | 23.20% | 16.06% | - | - | Upgrade |
Advertising Expenses | - | 127.26 | 54.49 | 429.28 | 429.72 | 364.34 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.